A Phase 3 interventional study of Stelara and Bmab1200 in Moderate to Severe Chronic Plaque Psoriasis, sponsored by Biocon Biologics UK Ltd. Completed at 1 site in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2025-09-12.
Sponsored by Biocon Biologics UK Ltd · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 766 studies in Psoriasis with a site in United States — 57 open to participants now, 88 under way, 19 of them phase 3. Psoriasis · United States.
Among the 766 studies in Psoriasis with a site in United States, this one is the 118th largest by enrollment of the 675 interventional ones that give a count, is one of 37 that started in 2022, is one of 188 in phase 3, and was the 647th registered.
2,032 studies on the registry are indexed under Psoriasis; 278 are open to participants now.
Browse Psoriasis studies →57 of the 766 studies in Psoriasis with a site in United States are open now. Recruiting first, the newest first:
Amgen · Sites in United States
Ages 18–60 · Healthy volunteers
Novartis Pharmaceuticals · Sites in United States
Ages 18–100
Modern Research Associates, PLLC · Sites in United States
Janssen Research & Development, LLC · Sites in United States
Ages 18+ · Women only
University of California, San Francisco · Sites in United States
Ages 18+ · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 175 Psoriasis studies recruiting now, 92 (53%) set no upper age limit and 67 (38%) stop at 75 or younger; 25 take children under 18; 42 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
766 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 99 · Phase 2 218 · Phase 3 193 · Phase 4 117
First in 1977; this study’s year is marked. 37 started in 2022.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 384 is above the median of 75 across 1,568 interventional studies indexed under Psoriasis.
Median enrollment 77 across the 675 interventional studies, 200 across the 90 observational. Of the 645 that completed or were terminated, 378 (59%) have results posted.
This tab as a report to print or save as PDF → With an account.
526 of 766 have an industry lead sponsor. The 10 most frequent:
Biocon Biologics UK Ltd is the lead sponsor of 5 studies on the registry; none are open to participants now.
Biocon Biologics UK Ltd has 2 studies filed under Psoriasis — fewer than ten, so there is no comparison to draw.
24 of the studies in Psoriasis with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05981118Phase 3Wake Forest University Health SciencesComparison of Post-Inflammatory Pigment Alteration After Psoriasis Treatment (PIPA - Dermavant) | 2027-01 |
| NCT03987763Bausch Health Americas, Inc.A Safety and Pharmacokinetics Study of IDP-122 Lotion in Pediatric Participants With Plaque Psoriasis | 2026-11 |
| NCT05570955Wake Forest University Health SciencesDeucravacitinib Adherence Study | 2026-11 |
| NCT04036188Wright State UniversityTriamcinolone With Vitamin D Synergistic Efficacy in Psoriasis | 2026-12 |
| NCT07221890Brigham and Women's HospitalA Trial of Academic Detailing to Promote Prescribing of Biosimilars | 2026-12-31 |
Add all 24 to your calendar (.ics) → With an account.
Among the 766 studies in Psoriasis with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This is a randomized, double-blind, active-controlled, parallel-group, multicenter study designed to compare the efficacy, safety, immunogenicity, and PK(Pharmacokinetic) of Bmab 1200 with Stelara in adult patients with moderate to severe chronic plaque psoriasis.
Approximately 384 patients with moderate to severe plaque psoriasis will be enrolled and randomly assigned to one of the 2 treatment groups in a 1:1 ratio (192 patients in the Bmab 1200 group and 192 patients in the Stelara group). Patients who are diagnosed as moderate to severe chronic plaque psoriasis for at least 6 months and are candidate for systemic therapy or phototherapy at the time of the screening visit will be enrolled. The study is planned to be conducted in Europe and North America across approximately 48 sites in 5 countries. The study will be conducted in an outpatient setting, and the participation for each patient will consist of a screening period (up to 4 weeks/28 days) and a double-blind, active-controlled treatment period (52 weeks) with a rerandomization step for switching therapy (Bmab 1200 with Stelara ) before Week 16 dosing. The treatment period before the switch is TP1(Treatment Period1) and post switch is TP2(Treatment Period 2) (from Week 16 dosing to prior to Week 28 dosing) and TP3 (Treatment Period3)(from Week 28 dosing to Week 52). The total duration of the study (excluding the screening period) will be 52 weeks.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patient with moderate to severe chronic plaque psoriasis as defined by BSA (Body surface area)involvement
Exclusion Criteria:
Patient who has a current or past history of any of the following infections:
Patient has current infection with virus (HBV) or virus (HCV) as per serological tests at screening.
Patient meeting any of the following tuberculosis (TB)-related conditions:
TP3 specific criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Postmenopausal
Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Live vaccines
Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bmab 1200 45 mg Bmab 1200 90 mg
Biological: Bmab1200
Stelara 45 mg Stelara 90 mg
Biological: Stelara
45 mg , 90 mg at Week 0, 4, 16, 28 and 40;During the study after receiving 2 doses , before dosing at Week 16 patients were re-randomised in a 1:1 ratio to receive either Bmab 1200 or Stelara .
45 mg , 90 mg at Week 0, 4, 16, 28 and 40
Psoriasis Area and Severity Index (PASI)
Percentage change from baseline in the Psoriasis Area and Severity Index score at Week 12
Time frame: Baseline to Week 12
PASI Score
Percentage change from baseline in the PASI score at Baseline through Week 28. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score
Time frame: Baseline through Week 28
PASI Improvement
PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Baseline through Week 28 and 52 PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score
Time frame: Baseline through Week 28
Static Physician's Global Assessment (sPGA)
Change from Baseline in sPGA During TP2. The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status
Time frame: Baseline through Week 28
Affected Body Surface Area
Change from baseline in affected body surface area at Weeks 28 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement
Time frame: Baseline through Week 28
Dermatology Life Quality Index Scores
Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 28 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.
Time frame: Baseline through Week 28
Dermatology Life Quality Index Scores
Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 52 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.
Time frame: Baseline through Week 52
Static Physician's Global Assessment (sPGA)
Change in Static Physician's Global Assessment (sPGA) at Weeks 52 The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status
Time frame: Baseline through Week 52
Affected Body Surface Area
Change from baseline in affected body surface area at Weeks 52 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement
Time frame: Baseline through Week 52
PASI Improvement
PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Week 52
Time frame: Baseline through week 52
PASI Score
Percentage change from baseline in the PASI score at Baseline through Week 52. The PASI (Psoriasis Area and Severity Index) is a score from 0 to 72 that measures psoriasis severity based on lesion redness, thickness, scaling, and body area affected. The body is divided into four regions, each scored separately. Scores are calculated using severity and area involvement, and are used to assess treatment response (e.g., PASI 50 = 50% improvement).
Time frame: Baseline through Week 52
Safety:-Treatment-emergent Adverse Events Including Adverse Events of Special Interest and Adverse Reactions During the Treatment Period
Time frame: Baseline to Week 52
Safety:- Injection-site Reactions
Injection-site reactions at Day 1, Week 4, Week 16, and throughout the study
Time frame: Baseline through Week 28 and 52
Safety:- Hypersensitivity
Hypersensitivity at Day 1, Week 4, Week 16, and throughout the study
Time frame: Baseline through Week 52
Immunogenicity:-Developing Antidrug Antibodies
Proportion of patients developing antidrug antibodies
Time frame: Baseline through Week 28
Immunogenicity:-Developing Antidrug Antibodies
Proportion of patients developing antidrug antibodies
Time frame: Postdosing Week 52
Developing Neutralizing Antibodies
Proportion of patients neutralizing antibodies
Time frame: Baseline through Week 28
Developing Neutralizing Antibodies
Proportion of patients neutralizing antibodies
Time frame: Postdosing Week 52
Pharmacokinetic:-Serum Concentrations
Serum concentrations of ustekinumab
Time frame: Postdosing on Week 28
Pharmacokinetic:-Serum Concentrations
Serum concentrations of Ustekinumab
Time frame: Postdosing on Week 52
The study was conducted in Europe and North America and enrolled patients across 41 sites in 5 countries.
| Milestone | Bmab1200 | Stelara | Bmab 1200- Bmab 1200 | Stelara-Stelara | Stelara-Bmab 1200 | Bmab 1200/Bmab 1200 | Stelara/Stelara | Stelara/Bmab 1200 |
|---|---|---|---|---|---|---|---|---|
| Started | 191 | 193 | 0 | 0 | 0 | 0 | 0 | 0 |
| Completed | 190 | 192 | 0 | 0 | 0 | 0 | 0 | 0 |
| Not completed | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| Milestone | Bmab1200 | Stelara | Bmab 1200- Bmab 1200 | Stelara-Stelara | Stelara-Bmab 1200 | Bmab 1200/Bmab 1200 | Stelara/Stelara | Stelara/Bmab 1200 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 185 | 94 | 92 | 0 | 0 | 0 |
| Completed | 0 | 0 | 171 | 87 | 86 | 0 | 0 | 0 |
| Not completed | 0 | 0 | 14 | 7 | 6 | 0 | 0 | 0 |
| Milestone | Bmab1200 | Stelara | Bmab 1200- Bmab 1200 | Stelara-Stelara | Stelara-Bmab 1200 | Bmab 1200/Bmab 1200 | Stelara/Stelara | Stelara/Bmab 1200 |
|---|---|---|---|---|---|---|---|---|
| Started | 0 | 0 | 0 | 0 | 0 | 168 | 81 | 84 |
| Completed | 0 | 0 | 0 | 0 | 0 | 163 | 79 | 82 |
| Not completed | 0 | 0 | 0 | 0 | 0 | 5 | 2 | 2 |
Percentage change from baseline in the Psoriasis Area and Severity Index score at Week 12
| Percentage change from baseline | Bmab1200 | Stelara |
|---|---|---|
| Psoriasis Area and Severity Index (PASI) | -79.87 ± 2.818 | -80.55 ± 2.783 |
Percentage change from baseline in the PASI score at Baseline through Week 28. PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score
| Percentage change from Baseline in Score | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| PASI Score | -95.50 ± 6.068 | -96.01 ± 6.461 | -95.44 ± 7.321 |
PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Baseline through Week 28 and 52 PASI is a quantitative rating score for measuring the severity of psoriatic lesions based on area coverage, plaque appearance, their response to therapy. 4 regions- head, upper limbs, trunk, and lower limbs are assessed separately for erythema, induration/thickness, and scaling. Degree of involvement is scored on a scale of 0 (no involvement) to 6 (90% to 100% involvement) for each region. Total score (sum of erythema, thickness, and scaling) is multiplied by the degree of involvement for each body region and then multiplied by constant. Sum of all lesion scores can range from 0 (no disease) to 72 (maximal disease), with the higher score indicating more severe disease. Change from baseline in PASI score indicates response to therapy. PASI 50 means ≥50% reduction from baseline in the PASI score
| Participants | Bmab1200 | Stelara-Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| PASI 50 | 168 | 80 | 84 |
| PASI 75 | 168 | 79 | 83 |
| PASI 90 | 140 | 70 | 67 |
Change from Baseline in sPGA During TP2. The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status
| score on a scale | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Static Physician's Global Assessment (sPGA) | -3.0 ± 1.21 | -2.9 ± 1.21 | -2.8 ± 1.28 |
Change from baseline in affected body surface area at Weeks 28 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement
| Percentage of total body surface area | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Affected Body Surface Area | -26.52 ± 15.152 | -25.91 ± 13.323 | -28.33 ± 17.251 |
Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 28 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.
| score on a scale | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Dermatology Life Quality Index Scores | -12.2 ± 6.84 | -10.5 ± 6.74 | -12.2 ± 7.08 |
Change from baseline in quality of life as measured by Dermatology Life Quality Index scores at Weeks 52 It is a 10-item patient-reported outcome questionnaire that, in addition to evaluating overall QoL, can be used to assess 6 different aspects that may affect QoL: symptoms and feelings, daily activities, leisure, work or school performance, personal relationships, and treatment. Nine of the 10 questions have response categories including "not relevant" (score of 0), "not at all" (score of 0), "a little" (score of 1), "a lot" (score of 2) and "very much" (score of 3); Question 7 is a "yes"/ "no" question where "yes" is scored as 3. Eight items also have a "Not relevant" option scored "0," which indicates no problems. Total scores range from 0 to 30 (less to more impairment) and a 5-point change from baseline is considered a clinically important difference.
| score on a scale | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Dermatology Life Quality Index Scores | -12.8 ± 6.73 | -11.5 ± 6.35 | -12.7 ± 6.98 |
Change in Static Physician's Global Assessment (sPGA) at Weeks 52 The sPGA is a quantitative rating score of the patient's psoriasis based on physician's assessment at a given time point according to the following categories: induration, erythema, and scaling. The sPGA is a 6-point scale and patient's psoriasis is graded as clear (0), minimal (1), mild (2), moderate (3), marked (4), severe (5). The sum of the scores for induration, erythema, and scaling will be divided by 3 to obtain a final sPGA score. lower score indicates better disease status
| score on a scale | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Static Physician's Global Assessment (sPGA) | -3.1 ± 1.21 | -3.0 ± 1.29 | -2.9 ± 1.20 |
Change from baseline in affected body surface area at Weeks 52 Total % BSA afflicted by psoriasis is estimated using a handprint of the patient at each visit . The entire palmar surface of the patient's handprint is assumed to correspond to approximately 1% of total BSA. Reduction in BSA indicates improvement
| Change from Baseline in %BSA | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Affected Body Surface Area | -27.42 ± 15.119 | -26.50 ± 13.160 | -28.90 ± 17.560 |
PASI improvement of ≥50% relative to baseline (PASI 50), PASI improvement of ≥75% relative to baseline (PASI 75), and PASI improvement of ≥90% relative to Week 52
| Participants | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| PASI 50 | 163 | 80 | 83 |
| PASI 75 | 159 | 80 | 81 |
| PASI 90 | 133 | 70 | 63 |
| Participants | Bmab1200 | Stelara | Stelara-Bmab1200 |
|---|---|---|---|
| Endometrial adenocarcinoma | 1 | 0 | 0 |
| Squamous cell carcinoma of the tongue | 1 | 0 | 0 |
| Angioedema | 0 | 1 | 0 |
| Rash maculo-papular | 0 | 1 | 0 |
| Abdominal pain | 1 | 0 | 0 |
| Jaundice cholestatic | 1 | 0 | 0 |
| Alcohol poisoning | 0 | 1 | 0 |
Injection-site reactions at Day 1, Week 4, Week 16, and throughout the study
No measurements were reported for this outcome.
Hypersensitivity at Day 1, Week 4, Week 16, and throughout the study
| participants | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Safety:- Hypersensitivity | 1 | 3 | 1 |
Proportion of patients developing antidrug antibodies
| participants | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| ADA positive | 162 | 88 | 86 |
| ADA negative | 21 | 6 | 5 |
| Patients with no post baseline ADA result | 2 | 0 | 1 |
Proportion of patients developing antidrug antibodies
| participants | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| ADA positive | 131 | 73 | 74 |
| ADA negative | 36 | 8 | 10 |
| Patients with no post baseline ADA result | 1 | 0 | 0 |
Proportion of patients neutralizing antibodies
| participants | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Nab reactive | 54 | 42 | 31 |
| Nab negative | 108 | 46 | 55 |
Proportion of patients neutralizing antibodies
| participants | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| Nab reactive | 27 | 19 | 12 |
| Nab negative | 104 | 54 | 62 |
Serum concentrations of ustekinumab
| ng/mL | Bmab 1200 (1 Injection) | Stelara-Stelara (1 Injection) | Stelara-Bmab 1200 (1 Injection) | Bmab 1200 (2 Injection) | Stelara-Stelara (2 Injection) | Stelara-Bmab 1200 ((2 Injection) |
|---|---|---|---|---|---|---|
| Pharmacokinetic:-Serum Concentrations | 678.308 ± 444.7791 | 589.780 ± 418.9308 | 620.793 ± 398.1352 | 796.833 ± 392.6448 | 1070.600 ± 522.0039 | 861.665 ± 549.4014 |
Serum concentrations of Ustekinumab
| ng/mL | Bmab 1200 (1 Injection) | Stelara-Stelara (1 Injection) | Stelara-Bmab 1200 (1 Injection) | Bmab 1200 (2 Injection) | Stelara-Stelara (2 Injection) | Stelara-Bmab 1200 (2 Injection) |
|---|---|---|---|---|---|---|
| Pharmacokinetic:-Serum Concentrations | 728.029 ± 477.1775 | 665.403 ± 379.9506 | 653.908 ± 415.8309 | 881.343 ± 510.0086 | 1008.382 ± 671.8667 | 898.450 ± 551.4494 |
Percentage change from baseline in the PASI score at Baseline through Week 52. The PASI (Psoriasis Area and Severity Index) is a score from 0 to 72 that measures psoriasis severity based on lesion redness, thickness, scaling, and body area affected. The body is divided into four regions, each scored separately. Scores are calculated using severity and area involvement, and are used to assess treatment response (e.g., PASI 50 = 50% improvement).
| Percentage change from Baseline | Bmab1200 | Stelara | Stelara-Bmab 1200 |
|---|---|---|---|
| PASI Score | -95.50 ± 7.507 | -96.60 ± 5.671 | -94.71 ± 7.950 |
Collected over Treatment Emergent Adverse Events (TEAEs) through the Study (Week 52). Non-serious events are listed at a 1% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Bmab1200 | 0/191 (0%) | 6/191 (3.1%) | 111/191 (58.1%) |
| Stelara | 0/101 (0%) | 0/101 (0%) | 48/101 (47.5%) |
| Stelara-Bmab1200 | 0/92 (0%) | 1/92 (1.1%) | 51/92 (55.4%) |
| Event | Bmab1200 | Stelara | Stelara-Bmab1200 |
|---|---|---|---|
| Cholecystitis acuteHepatobiliary disorders | 0/191 | 0/101 | 1/92 |
| Squamous cell carcinoma of the tongueNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/191 | 0/101 | 0/92 |
| Endometrial adenocarcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/191 | 0/101 | 0/92 |
| Acute myocardial infarctionCardiac disorders | 1/191 | 0/101 | 0/92 |
| Cardiac failureCardiac disorders | 1/191 | 0/101 | 0/92 |
| Abdominal painGastrointestinal disorders | 1/191 | 0/101 | 0/92 |
| Jaundice cholestaticHepatobiliary disorders | 1/191 | 0/101 | 0/92 |
| Uterovaginal prolapseReproductive system and breast disorders | 1/191 | 0/101 | 0/92 |
| Ischaemic strokeNervous system disorders | 1/191 | 0/101 | 0/92 |
| Event | Bmab1200 | Stelara | Stelara-Bmab1200 |
|---|---|---|---|
| NasopharyngitisInfections and infestations | 18/191 | 6/101 | 8/92 |
| Upper respiratory tract infectionInfections and infestations | 6/191 | 1/101 | 6/92 |
| Alanine aminotransferase increasedInvestigations | 12/191 | 6/101 | 2/92 |
| Blood triglycerides increasedInvestigations | 11/191 | 3/101 | 3/92 |
| InfluenzaInfections and infestations | 4/191 | 5/101 | 5/92 |
| Aspartate aminotransferase increasedInvestigations | 7/191 | 2/101 | 0/92 |
| Urinary tract infectionInfections and infestations | 6/191 | 2/101 | 3/92 |
| COVID-19Infections and infestations | 4/191 | 0/101 | 3/92 |
| RhinitisInfections and infestations | 2/191 | 2/101 | 3/92 |
| ProteinuriaRenal and urinary disorders | 4/191 | 1/101 | 3/92 |
Patient demographics and baseline characteristics provided on FAS which consist of all participants who signed the ICF and were randomized
| Age, Continuous(years) | Bmab1200 | Stelara | Total |
|---|---|---|---|
| Mean | 42.5 ± 13.09 | 43.9 ± 13.58 | 43.2 ± 13.34 |
| Sex: Female, Male(Participants) | Bmab1200 | Stelara | Total |
|---|---|---|---|
| Female | 70 | 57 | 127 |
| Male | 121 | 136 | 257 |
| Race/Ethnicity, Customized(Subject) | Bmab1200 | Stelara | Total |
|---|---|---|---|
| Hispanic or Latino | 6 | 6 | 12 |
| Not Hispanic or Latino | 185 | 187 | 372 |
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Black or African American | 1 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| White | 190 | 192 | 382 |
| Other | 0 | 0 | 0 |
| Region of Enrollment(Subject) | Bmab1200 | Stelara | Total |
|---|---|---|---|
| Europe | 189 | 189 | 378 |
| United States | 2 | 4 | 6 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Jun 2022 to primary completion in Jan 2023, 6 months.
Results were first posted in Sep 2025, 2 years 7 months after primary completion. A results delay was requested in Nov 2023.
Of 216 industry-sponsored phase 3 interventional studies under Psoriasis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 25. This study's 6 months is below that.
Counting every sponsor, half of 226 studies reached it within 15 months; a quarter within 10 and three quarters within 26.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Biocon Biologics UK Ltd